This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT
2A
and 5-HT
2C
receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production.
The compounds according to the invention can be represented by general Formula (I)
and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim
1.
这项发明涉及一种新的取代四环
四氢呋喃、
吡咯烷和
四氢噻吩衍
生物,其具有对5-HT2A和5-HT2C受体,特别是对
多巴胺D2受体和去甲肾上腺再摄取抑制性能的结合亲和力,并且还包括根据本发明的化合物的制药组合物,其用作药物,特别是用于预防和/或治疗一系列精神和神经疾病,特别是某些精神病、心血管和胃动力障碍,以及其制备方法。根据本发明的化合物可以用一般式(I)表示,并包括其药学上可接受的酸或碱盐,其立体
化学异构体形式,其N-氧化物形式和其前药,其中所有取代基在权利要求1中定义。